The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice by Ansari, Mohammed Javeed I. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/07/63/7 $8.00
Volume 198, Number 1, July 7, 2003 63–69
http://www.jem.org/cgi/doi/10.1084/jem.20022125
 
63
 
The Programmed Death-1 (PD-1) Pathway Regulates 
Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
 
Mohammed Javeed I. Ansari,
 
1 
 
Alan D. Salama,
 
1, 3 
 
Tanuja Chitnis,
 
2, 3
 
R. Neal Smith,
 
4 
 
Hideo Yagita,
 
5 
 
Hisaya Akiba,
 
5 
 
Tomohide Yamazaki,
 
5
 
Miyuki Azuma,
 
6 
 
Hideyuki Iwai,
 
6 
 
Samia J. Khoury,
 
2
 
Hugh Auchincloss, Jr.,
 
4 
 
and Mohamed H. Sayegh
 
1, 3
 
1
 
Laboratory of Immunogenetics and Transplantation and 
 
2
 
Centre for Neurologic Diseases, Brigham and Women’s 
Hospital, 
 
3
 
Nephrology Division, The Children’s Hospital, and 
 
4
 
Department of Surgery and Pathology, 
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115
 
5
 
Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
 
6
 
Department of Molecular Immunology, Tokyo Medical and Dental University, Tokyo 113-8549, Japan
 
Abstract
 
Programmed death-1 (PD-1) receptor, an inhibitory costimulatory molecule found on acti-
vated T cells, has been demonstrated to play a role in the regulation of immune responses and
peripheral tolerance. We investigated the role of this pathway in the development of autoim-
mune diabetes. PD-1 or PD-L1 but not PD-L2 blockade rapidly precipitated diabetes in predi-
abetic female nonobese diabetic (NOD) mice regardless of age (from 1 to 10-wk-old), although it
was most pronounced in the older mice. By contrast, cytotoxic T lymphocyte–associated anti-
gen 4 (CTLA-4) blockade induced disease only in neonates. Male NOD mice also developed
diabetes after PD-1–PD-L1 pathway blockade, but NOR mice, congenic to NOD but resis-
tant to the development of diabetes, did not. Insulitis scores were significantly higher and fre-
quency of interferon 
 
 
 
–producing GAD-reactive splenocytes was increased after PD-1–PD-L1
pathway blockade compared with controls. Interestingly, PD-L1 but not PD-L2 was found to
be expressed on inflamed islets of NOD mice. These data demonstrate a central role for PD-1–
PD-L1 interaction in the regulation of induction and progression of autoimmune diabetes in
the NOD mouse and provide the rationale to develop new therapies to target this costimula-
tory pathway in this disease.
Key words: diabetes mellitus, insulin-dependent • mice, inbred NOD • autoimmunity • self-
tolerance • programmed cell death protein 1
 
Introduction
 
Termination of an immune response is achieved through a
number of different mechanisms (1) including regulatory
costimulatory molecules (2). Overall, the balance between
the positive and negative signaling costimulatory pathways
dictates the fate of individual T cells and the immune
response. The inhibitory costimulatory molecule pro-
grammed death-1 (PD-1)
 
* 
 
and its ligands, PD-L1 and PD-
L2, have been shown to play an important role in regulat-
ing T cell activation and peripheral tolerance (3–6). PD-1
deficiency leads to lupus-like syndrome with glomerulone-
phritis and arthritis or fatal dilated cardiomyopathy, de-
pending on the genetic background of the animal (7, 8).
We investigated the role of this novel inhibitory costimula-
tory pathway in regulating the autoimmune response in
nonobese diabetic (NOD) mice.
The NOD mouse has proved to be a valuable model for
studying autoimmune diabetes. Indeed, the recent report
by Herold et al. (9) on the efficacy of nonmitogenic anti-
CD3 mAb in humans with type 1diabetes was a direct
translation of the original studies reported in the NOD
mouse almost a decade earlier (10). In NOD mice, spon-
taneous insulitis, the hallmark pathologic lesion, evolves
through several characteristic stages that begin with peri-
insulitis and end with invading and destructive insulitis
and overt diabetes. Peri-insulitis is first observed at 3–4 wk
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Abbreviations used in this paper:
 
 CTLA-4, cytotoxic T lymphocyte–
associated antigen 4; EAE, experimental autoimmune encephalomyelitis;
NOD, nonobese diabetic; PD-1, programmed death-1.T
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of age, invading insulitis at 8–10 wk, and destructive insu-
litis appears just before the onset of clinical diabetes, with
the earliest cases at 10–12 wk. By 20 wk of age, 70–80%
of females become diabetic. By contrast, in male NOD
mice, diabetes is typically delayed with only a 40–50% in-
cidence by 30 wk of age (11). Thus, before islet cell dam-
age, a period of nondestructive inflammation is observed
with a heavy cellular infiltrate surrounding the individual
islets beginning at least 7 wk before the onset of overt dia-
betes (12). Interestingly, insulitis does not uniformly
progress to disease. For example, in male mice insulitis is
as prevalent as in females, but fewer males go on to de-
velop overt diabetes (11). The mechanisms regulating the
initiation and progression of insulitis to overt diabetes are
unclear. However, a role for negative T cell signaling
pathways through inhibitory receptors has been demon-
strated in the initiation of disease in neonatal animals. Us-
ing the BDC2.5/NOD TCR transgenic model, in which
diabetes develops in 15–30% of animals at 5–6 mo of age,
blocking cytotoxic T lymphocyte–associated antigen 4
(CTLA-4) induced disease by 3 wk of age in almost all of
the transgenic animals. Interestingly, late (after 17 d of
age) blockade did not induce disease (13). Similarly, early
(at 2–3 wk of age) anti–B7-1 mAb treatment of female
NOD mice increased the incidence of diabetes and
CTLA-4Ig or anti–B7-2 mAb treatment reduced the inci-
dence of diabetes, whereas late (at 10 wk of age) treatment
with any of these reagents had no effect on disease pro-
gression (14), suggesting that CD28/B7/CTLA-4 costim-
ulatory pathway plays an important role in regulating dis-
ease induction but not progression. By contrast, our data
demonstrate that PD-1–PD-L1 pathway is involved in the
regulation of both initiation and progression of autoim-
mune diabetes in NOD mice.
 
Materials and Methods
 
Mice.
 
Female and male NOD, female NOR, BALB/c mice
of various ages, and female NOD.SCID mice were obtained
from The Jackson Laboratory and cared for in accordance with
institutional guidelines.
 
Antibodies and Treatment Protocol.
 
The anti–mouse PD-1
mAb (J43, hamster IgG) has been described (4). The anti–mouse
PD-L1 mAb (MIH6, rat IgG2a) and the anti–mouse PD-L2
mAb (TY25, rat IgG2a) were generated as recently described
(15). PD-1–transfected BHK cells (baby hamster kidney cell line;
reference 4) were pretreated with control hamster IgG (BD Bio-
sciences) or the anti–PD-1 mAb (J43) and then stained with PD-
L1-Ig (16) or PD-L2-Ig (17) followed by PE-labeled goat anti–
human IgG (Caltag). Flow cytometry analysis showed that the
anti–PD-1 mAb inhibited the binding of both PD-L1-Ig and
PD-L2-Ig to PD-1 transfectants (Fig. 1 A). PD-L1-Ig and PD-
L2-Ig were also preincubated with control rat IgG2a (BD Bio-
sciences), anti–PD-L1 mAb (MIH6), or anti–PD-L2 mAb
(TY25), and then used for staining of the PD-1/BHK cells. Flow
cytometry analysis showed that anti–PD-L1 mAb inhibited the
binding of PD-L1-Ig and anti-PD-L2 inhibited the binding of
PD-L2-Ig specifically (Fig. 1 B). Fab fragments of these mAbs
showed similar results (not depicted). These results indicate the
blocking properties of the mAbs used in this study. Anti–CTLA-4
(4F10) mAb-producing hybridoma was provided by J. Bluestone
(University of California San Francisco, San Francisco, CA). All
mAbs were manufactured and purified by BioExpress Inc. Ham-
ster IgG (ICN Pharmaceuticals Inc.) and rat IgG (Sigma-Aldrich)
served as controls. All mAbs were given intraperitoneally: 500 
 
 
 
g
on day 0, followed by 250 
 
 
 
g on days 2, 4, 6, 8, and 10.
 
Monitoring for Diabetes.
 
Clinical diabetes was defined as a ran-
dom blood glucose reading of 
 
 
 
250 mg/dL for three consecutive
days. Blood glucose was measured by Accu-Chek Advantage glu-
cometers (Roche Diagnostics). 4- and 10-wk-old mice were
monitored daily by measuring blood glucose for the first 3 wk
followed by three times a week until the mice were killed. The
neonatal mice were monitored initially for urine glucose on alter-
Figure 1. Blocking properties of mAbs against PD-1, PD-L1, and PD-L2.
(A) Anti–PD-1 (J43) inhibits binding of both PD-L1-Ig and PD-L2-Ig (bold
lines) to PD-1 transfectants. Dashed lines indicate staining with control
human IgG. (B) Anti–PD-L1 (MIH6) inhibits PD-L1-Ig binding and
anti–PD-L2 (TY25) inhibits PD-L2-Ig binding to PD-1 transfectants
(bold lines). Dashed lines indicate staining with control human IgG.T
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nate days until 3 wk of age, followed by blood glucose measure-
ment according to the above schedule.
 
Histopathology.
 
Mice in the 4- and 10-wk-old group were
killed on days 11–13 after initiation of treatment for histology
specimens and harvesting of spleens for ELISPOT. Pancreas sec-
tions were stained with hematoxylin and eosin. Immunoperoxi-
dase staining of frozen sections of pancreata for PD-1, PD-L1,
and PD-L2 was performed using the appropriate purified mAbs
and isotype controls using the avidin-biotin technique (Vector
Laboratories). The sections were counter stained with hematoxy-
lin. Insulitis scoring was performed as described by Yoon et al.
(18) by examining at least 20 islets per mouse and graded as fol-
lows: grade 0, normal islets; grade 1, mononuclear infiltration,
largely in the periphery, in 
 
 
 
25% of the islet; grade 2, 25–50% of
islet showing mononuclear infiltration; grade 3, 
 
 
 
50% of islet
showing mononuclear infiltration; and grade 4, small, retracted
islet with few mononuclear cells.
 
Micro-Insulin Autoantibody Assay.
 
This assay was performed
by G. Isenbarth’s laboratory (Barbara Davis Center, Denver,
CO), according to previously published methods (19).
 
ELISPOT.
 
Splenocytes from treated and control mice were
obtained as single cell suspensions. The ELISPOT assay was
adapted to measure IFN-
 
 
 
–secreting cells. ELISASpot plates
(Cellular Technology Limited) were coated with capture mAb
against IFN-
 
  
 
(BD Biosciences) in PBS and left overnight at
4
 
 
 
C. The plates were blocked with PBS-BSA 1% for 1 h and
then washed with PBS. 10
 
6 
 
splenocytes were added to each well
in 100 
 
 
 
l complete RPMI medium containing 10% fetal calf
serum (Sigma-Aldrich), 2 mM 
 
l
 
-glutamine, 100 U/ml penicil-
lin/streptomycin (BioWhittaker), and 50 mM 2-mercaptoetha-
nol (Sigma-Aldrich). Control wells contained responder sple-
nocytes plus medium alone. Test cells were added with GAD
antigen (Diamyd Inc.) at 10 
 
 
 
g/ml. After 48 h, the plates were
washed, biotinylated detection mAbs (BD Biosciences) were
added, and the plates were left for an additional overnight incu-
bation at 4
 
 
 
C. After further washing, horseradish peroxidase–
conjugated avidin (DakoCytomation) was added for 2 h at
room temperature. Color was developed with AEC (Sigma-
Aldrich). The resulting spots were counted on a computer-
assisted ELISASpot Image Analyzer (Cellular Technology
Limited). The frequencies were then expressed as cytokine-
producing cells per million splenocytes.
 
Flow Cytometry.
 
Single cell splenocyte suspensions were ob-
tained and two color flow cytometry was performed. Cells
were left unstimulated or activated with 10 
 
 
 
g/ml plate-bound
anti-CD3 mAb (BD Biosciences) for 72 h, after which 10
 
6 
 
cells
were stained with anti–CD3-FITC (BD Biosciences) and either
anti–PD-1–PE or anti–PD-L1–PE (eBioscience). Hamster
IgG–PE or Rat Ig–PE (BD Biosciences) served as controls.
Cells were analyzed on a FACSCalibur™ (Becton Dickinson)
and the percentages of CD3
 
  
 
or CD3
 
  
 
cells expressing PD-1 or
PD-L1 were quantified using CELLQuest™ software (Becton
Dickinson).
 
Results and Discussion
 
To explore the involvement of PD-1 and its ligands in
the development of diabetes, we administered blocking
mAbs against PD-1, PD-L1, and PD-L2 into prediabetic
female NOD mice of various ages. In 10-wk-old female
NOD mice, PD-L1 blockade by anti–PD-L1 mAb precipi-
tated diabetes in 82.4% of the animals 6 d after initiation of
therapy with nearly a quarter developing diabetes after a
single injection of the antibody. Anti–PD-1 mAb had a
similar effect (76.5% of mice developed diabetes). In con-
trast, only one mouse in the anti–PD-L2 mAb-treated
group developed diabetes (not statistically significant over
controls) and none in the anti–CTLA-4 mAb-treated
group for the duration of follow up. The incidence of dia-
betes in our colony of unmanipulated NOD female mice is
20% at 10 wk of age, and 
 
 
 
70% by 20 wk of age. How-
ever, in keeping with previous reports, control IgG–treated
animals had slightly delayed onset of overt diabetes (20),
demonstrating that the accelerated onset in our treated co-
hort was a true biological effect related to PD-1–PD-L1
blockade (Fig. 2 A). In 4-wk-old female NOD mice, anti–
PD-L1 mAb treatment induced diabetes in 86.2% of mice
by 20 d after initiation of treatment with the first cases ap-
pearing around day 10. Anti–PD-1 mAb had a less pro-
nounced effect with over a third (41.4%) developing diabe-
tes by day 15, and none of the animals developed diabetes
in the anti–PD-L2 mAb-treated group. Again, anti–
CTLA-4 mAb and control IgG did not result in diabetes
for the duration of follow up (Fig. 2 B). By contrast, in
1-wk-old female NOD mice, anti–CTLA-4 mAb treat-
ment was able to induce diabetes in 54.5% of mice by 28 d
after initiation of treatment with the first cases appearing
around day 21. PD-1–PD-L1 blockade was able to induce
diabetes in 47.6% of mice in the anti–PD-1 group and
57.1% in the anti–PD-L1 group (not statistically significant
vs. CTLA-4) and this effect was not seen until day 28,
more than 1 wk after the first cases seen with anti–CTLA-4
antibody treatment (Fig. 2 C).
At 10 wk of age, in male NOD mice that rarely develop
overt diabetes, PD-1–PD-L1 blockade had a similar effect
to that seen in female NOD mice of the same age, with an
80% incidence of diabetes after anti–PD-1 and 100% after
anti–PD-L1 mAb treatment. At 4 wk of age, anti–PD-1
mAb treatment had no effect whereas anti–PD-L1 mAb in-
duced diabetes in 75% of mice by day 14 after initiation of
treatment. Neither NOR mice (Fig. 2, D and E) nor
BALB/c mice (not depicted) developed diabetes after PD-
1–PD-L1 blockade, indicating that the effect observed in
NOD mice is not due to nonspecific islet cell toxicity re-
lated to mAb treatment.
We then examined the pathology of pancreata of young
(4–5-wk-old) diabetic mice from the experimental group
in which treatment was started at 1 wk of age for evidence
of insulitis to compare the effect of PD-1 or PD-L1 block-
ade with control mice (which normally exhibit minimal
insulitis at this age) and with that of CTLA-4 blockade
(the only experimental age group where CTLA-4 block-
ade induced disease). Pathologically, there was marked de-
structive insulitis in the young diabetic animals after either
CTLA-4, PD-1, or PD-L1 blockade, whereas the control
animals had minimal inflammation of the islets at that time
(Fig. 3, A–D). Insulitis scores were significantly higher in
the PD-1 (mean score 1.249 
 
  
 
0.2349) and PD-L1 (mean
score 2.275 
 
  
 
0.1987) blockade groups compared with
the control group (mean score 0.03634 
 
  
 
0.01987, P 
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0.001 for both anti–PD-1 and anti–PD-L1 vs. controls;
Fig. 2 F).
To assess whether PD-1–PD-L1 blockade exerted some
of its diabetogenic effect by its action on B cells, we mea-
sured insulin autoantibody levels in 4–5-wk-old mice
treated with PD-1–PD-L1 blockade, but found no correla-
tion between insulin autoantibody levels and development
of diabetes. Specifically, some animals developed diabetes
with no antibodies and some developed antibodies but did
not develop diabetes (not depicted).
To assess the effect of PD-1–PD-L1 blockade on islet-
reactive T cells, we transplanted diabetic female NOD
mice (at least 2 wk after the last mAb treatment) with islet
isografts from female NOD.SCID mice. These isografts re-
establish euglycaemia in the recipients until a time that they
are destroyed by the islet-specific autoreactive T cells (21).
In the mice that had developed spontaneous diabetes, islet
isografts were rejected within 21 d (median survival was
15.5 d). By contrast, in the mice rendered diabetic after
PD-1–PD-L1 blockade, islet isografts suffered accelerated
rejection with five of six recipients losing their grafts within
3 d. These data suggest that after PD-1–PD-L1 blockade,
autoaggressive T cells might be expanded in number or
maintained in a heightened state of activation, capable of
full effector function leading to accelerated destruction of
islet isografts.
To address these two possibilities, we quantified the
frequencies of IFN-
 
 
 
–producing GAD-reactive T cells
and assessed the state of activation of T cells in mice re-
ceiving anti–PD-1 mAb, anti–PD-L1 mAb, or control
IgG. Using ELISPOT analysis we found increased fre-
quency of IFN-
 
 
 
–producing GAD-reactive splenocytes in
4- or 10-wk-old mice from anti–PD-1 or anti–PD-L1
mAb-treated group, compared with age-matched control
Figure 2. PD-1–PD-L1 blockade accelerates autoimmune diabetes in
NOD mice. All p-values are for comparisons with respective controls.
(A) Diabetes-free survival after PD-1–PD-L1 blockade in 10-wk-old
female NOD mice: anti–PD-1 ( ; n   17; P   0.0001), anti–PD-L1
( ; n   17; P   0.0001), anti–PD-L2 ( ; n   7; P   0.1904), anti–
CTLA-4 ( ; n   6; P   NS), and control antibody ( ; n   12) treat-
ment. (B) Diabetes-free survival after PD-1–PD-L1 blockade in 4-wk-
old female NOD mice: anti–PD-1 ( ; n   15; P   0.0184), anti–PD-L1
( ; n   18; P   0.0001), anti–PD-L2 ( ; n   7; P   NS), anti–
CTLA-4 ( ; n   10; P   NS), and control antibody ( ; n   12) treat-
ment. (C) Diabetes-free survival after PD-1–PD-L1 blockade in
1-wk-old female NOD mice: anti–PD-1 ( ; n   18; P   0.0071),
anti–PD-L1 ( ; n   18; P   0.0018), anti–PD-L2 ( ; n   11; P  
NS), anti–CTLA-4 ( ; n   11; P   0.0016), and control antibody ( ;
n   10) treatment. (D) Diabetes-free survival after PD-1–PD-L1 block-
ade in 10-wk-old male NOD mice: anti–PD-1 ( ; n   5; P   0.0126),
anti–PD-L1 ( ; n   5; P   0.0126), and control antibody ( ; n   5)
treatment. In 10-wk-old female NOR mice: anti–PD-1 ( ; n   5; P  
NS) and anti–PD-L1 ( ; n   5; P   NS) treatment. (E) Diabetes-free
survival after PD-1–PD-L1 blockade in 4-wk-old male NOD mice:
anti–PD-1 ( ; n   5; P   NS), anti–PD-L1 ( ; n   6; P   0.038),
control Ig ( ; n   5) treatment. In 4-wk-old female NOR mice: anti–
PD-1 ( ; n   5; P   NS) and anti–PD-L1 ( ; n   6; P   NS) treat-
ment. (F) Insulitis scores in 4–5-wk-old female NOD mice treated with
anti–PD-1 ( ; mean score 1.249   0.2349; P   0.001), anti–PD-L1
( ; mean score 2.275   0.1987; P   0.001), and control IgG ( ; mean
score 0.03634   0.01987).
Figure 3. PD-1–PD-L1 and CTLA-4 blockade accelerates insulitis in
prediabetic female NOD mice. (A) Islets from control IgG–treated mouse
at 5 wk of age. (B–D) Inflamed islets from anti–CTLA-4, anti–PD-1, or
anti–PD-L1 mAb-treated mice, respectively, at 5 wk of age (all stained
with hematoxylin and eosin;  400).T
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IgG–treated mice (Fig. 4). Flow cytometry analysis
showed that the percentages of CD4  CD25  and CD4 or
CD8 T cells expressing a CD62Llow CD44high memory/ef-
fector phenotype were similar in the anti–PD-L1, anti–
PD-1, and control groups (not depicted). Therefore,
taken together, it appears that PD-1–PD-L1 blockade re-
sulted in expansion of activated GAD-reactive cells. This
is consistent with the results of Salama et al. (22), who
used antigen-specific transgenic T cells and demonstrated
a critical role of PD-1 in regulating autoimmune enceph-
alomyelitis in the C57BL/6 mouse model. Interestingly,
blockade of PD-L1 resulted in greater insulitis, overt dia-
betes, and higher frequencies of GAD-reactive T cells
than PD-1 blockade. These data are in keeping with a re-
cent report indicating that PD-L1 may mediate apoptosis
of activated T cells through ligation of a receptor distinct
from PD-1 (16).
MHC class I–restricted CD8  T cells play an important
role in the initiation and mediation of autoimmune   cell
destruction (23). CD8  T cells are more sensitive to
the PD-1–PD-L1 inhibitory pathway and costimulation
through CD28 can overcome PD-1–mediated inhibition
of CD4  but not CD8  T cell responses through IL-2
production (24). This might be of significance in diabetes
where in the context of inflamed islets, autoreactive CD8 
T cells would be inactivated after encounter with MHC
class I on parenchymal cells coexpressing PD-L1 (5, 25).
PD-L1 expression has also been demonstrated in a variety
of human cancers and tumor cell lines (16). Iwai et al.
(26), in a tumor immunity model, recently demonstrated
that transgenic expression of PD-L1 in tumor cells ren-
dered them less susceptible to the specific T cell antigen
receptor–mediated lysis by cytotoxic T cells. We exam-
ined the expression of PD-1, PD-L1, and PD-L2 in NOD
islets in unmanipulated animals with established insulitis.
No staining was seen with isotype control or anti–PD-L2
mAb. PD-1 expression was seen only on infiltrating cells
in the inflamed islets, whereas PD-L1 was limited to in-
Figure 4. Increased  frequency
of IFN- –producing GAD-spe-
cific splenocytes in NOD mice
treated with anti–PD- or anti–
PD-L1 mAb. ELISPOT responses
are expressed as number of IFN- 
spots per million splenocytes from
anti–PD-1 mAb, anti–PD-L1
mAb, and control IgG–treated
4-wk-old female NOD mice.
Figure 5. (A) PD-L1 expression in inflamed islets
of NOD mice and PD-1 expression on infiltrating
cells. Inflamed islets from 10-wk-old unmanipulated
prediabetic female NOD mice showing negative
staining with isotype control Ig, positive PD-1 stain-
ing of infiltrating cells (arrows), positive PD-L1 stain-
ing of islets, and negative PD-L2 staining ( 400). (B)
Injected anti–PD-L1 mAb binds to islets. Inflamed is-
let, from a 10-wk-old NOD mouse that developed
diabetes after injection of anti–PD-L1, showing posi-
tive direct staining with anti–rat antibody ( 400).T
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flamed islets from unmanipulated 10-wk-old female NOD
mice (Fig. 5 A). Uninflamed islets from younger NOD
mice and those from BALB/c and C57Bl/6 mice lacked
PD-L1 expression. Moreover, direct staining with anti–rat
antibody of inflamed islets from a mouse that developed
diabetes after anti–PD-L1 mAb treatment (Fig. 5 B) con-
firmed the localization of PD-L1 in the inflamed islets.
These findings and the fact that a significant number of
10-wk-old female NOD mice developed diabetes after a
single injection of the mAbs suggests that this pathway
may inhibit the function of islet-reactive T cells already
present at the site of inflammation. However, in younger
mice, in whom islet expression of PD-L1 was not seen,
blockade of this pathway also precipitated diabetes, albeit
more gradually, and increased GAD-reactive T cell fre-
quencies were found in the spleens of anti–PD-1– and
anti–PD-L1–treated mice. Thus, the PD-1 pathway may
regulate effector T cells within the target tissue and within
the peripheral lymphoid organs. Moreover, in the experi-
mental autoimmune encephalomyelitis (EAE) model, the
findings that PD-L2 blockade augments disease despite
minimal PD-L2 expression in the brain of animals with
EAE (22) provides further evidence for lymphoid com-
partment regulation by this pathway.
In the case of NOD mice, this inhibitory pathway ulti-
mately fails resulting in diabetes as the mice age. This may
in part relate to decreased levels of expression of PD-L1 or
PD-1 in aging mice. Indeed, we found that anti-CD3–acti-
vated splenocytes from female NOD mice had decreasing
percentages of cells expressing PD-L1 (Fig. 6, A–D) and
decreasing mean fluorescence intensity of PD-L1 expres-
sion (not depicted) on both CD3  and CD3  cells with in-
creasing age, compared with age-matched control BALB/c
mice. We found no change in PD-1 expression with age
(not depicted).
Given the autoimmune phenotypes of PD-1–deficient
mice and other in vitro data (7, 8), it appears that the PD-1
pathway is inhibitory. Our data demonstrate an impor-
tant role for this pathway in the regulation of autoim-
mune diabetes in NOD mice, where PD-1–PD-L1 inter-
action inhibits the activation, expansion, and effector
function of islet-reactive T cells. However, there are data
suggesting that PD-L1 (B7-H1) costimulates T cell prolif-
eration and IL-10 secretion (27), whereas PD-L2 (B7-
DC) may activate naive T cells in vitro and promote Th1
cytokine production (17). Further, cross-linking of PD-
L2 by IgM antibodies has been shown to activate the im-
mune functions of dendritic cells and potentiate T cell re-
sponses (28). Therefore, there is also a remote possibility
that the antibodies used in our experiments are stimula-
tory in vivo. However, this seems unlikely because in
vivo administration of the anti–PD-1 Fab fragments aug-
ments immune responses to the same extent as the whole
antibody (unpublished data). These data and the disparate
effects of anti–PD-L1 and anti–PD-L2 mAbs in NOD di-
abetes and EAE models (22) argue against the antibodies
acting agonistically in vivo.
This is the first study to establish, in the NOD mouse,
that there is negative physiologic regulation of autoim-
mune diabetes by CTLA-4 only in the early stages of life
compared with the PD-1–PD-L1 pathway, which appears
to be regulating autoreactive T cells throughout the life
span of the animal. This may suggest differing modes of ac-
tion of these two pathways. The CTLA-4 inhibitory path-
way appears to only inhibit activation of naive T lympho-
cytes but the PD-1 pathway appears to inhibit both
activation of naive T cells and effector function of acti-
vated autoreactive cells. Further, there is PD-L1 expression
in the inflamed islets of Langerhans, suggesting a novel
mechanism of down-regulating lymphocyte function at
the site of inflammation by parenchymal cells. Therefore,
although both CTLA-4 and PD-1 are important in regu-
lating the initiation of the autoimmune response, PD-1 ap-
pears to be critical for progression of autoimmune diabetes.
These data provide a rationale for therapeutic manipula-
tion of the PD-1 pathway in the treatment of autoimmune
disease, as has recently been suggested in a transplantation
model (29).
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Figure 6. PD-L1 expression is down-regulated on stimulated spleno-
cytes of older NOD mice. Expression of PD-L1 on CD3  (A and B) or
CD3  (C and D) splenocytes of female NOD (A and C) or BALB/c (B
and D) mice of various ages before and after stimulation with immobi-
lized anti-CD3 mAb for 72 h. *, P   0.01 and **, P   0.05 versus stimu-
lated CD3  cells from 9-wk-old female NOD mice.T
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